Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - mycobacterium paratuberculosis - unknown - mycobacterium paratuberculosis vaccine active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

novavive australasia pty ltd - mycobacterium cell wall fraction; gentamicin - parenteral liquid/solution/suspension - mycobacterium cell wall fraction ungrouped active 1.0 mg/ml; gentamicin antibiotic other 30.0 ug/ml - immunotherapy - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - equine respiratory tract infections vira | infections of viral origin

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - mycobacterium paratuberculosis; thiomersal - misc. vaccines or anti sera - mycobacterium paratuberculosis vaccine active 2.5 mg/ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - goat | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether - johne's disease | mycobacterium paratuberculosis shedding

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

kahma biotech (pty) ltd - suspension - see ingredients - each vial contains mycobacterium bovis 30,0 mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - mycobacterium paratuberculosis - misc. vaccines or anti sera - mycobacterium paratuberculosis vaccine active 2.5 mg/ml - immunotherapy

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - mycobacterium paratuberculosis - mycobacterium paratuberculosis 2.5 g/litre - vaccine

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - mycobacterium paratuberculosis - mycobacterium paratuberculosis 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

asurequality limited - mycobacterium bovis - mycobacterium bovis 30 thou iu/ml - diagnostic antigens

New Zealand - English - Ministry for Primary Industries

asurequality limited - mycobacterium avium - mycobacterium avium 25 thou iu/ml - diagnostic antigens

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - bacillus calmette-guerin substrain tice live antigen (unii: 2xq558l16z) (bacillus calmette-guerin substrain tice live antigen - unii:2xq558l16z) - bacillus calmette-guerin substrain tice live antigen 50 mg in 50 ml - tice® bcg is indicated for: - the treatment and prophylaxis of carcinoma in situ (cis) of the urinary bladder - the prophylaxis of primary or recurrent stage ta and/or t1 papillary tumors following transurethral resection (tur) limitations of use: - tice bcg is not recommended for stage tag1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. - tice bcg is not indicated for papillary tumors of stages higher than t1. tice® bcg should not be used in immunosuppressed patients with congenital or acquired immune deficiencies, whether due to concurrent disease (e.g., aids, leukemia, lymphoma) cancer therapy (e.g., cytotoxic drugs, radiation), or immunosuppressive therapy (e.g., corticosteroids). treatment should be postponed until resolution of a concurrent febrile illness, urinary tract infection, or gross hematuria. seven to 14 days should elapse before bcg is administered following biopsy, tur, or traumatic catheterization. tice bcg should not be administered to persons with active tuberculosis. active tuberculosis should be ruled out in individuals who are ppd positive before starting treatment with tice bcg.